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Résumé 
Justification: 
  Le glaucome entraîne une perte progressive de la vision causée par la 
détérioration du nerf optique. Le glaucome est répandu dans le monde et cause 
la cécité dans environ sept millions de personnes. Le glaucome touche plus de 
400 000 Canadiens et sa prévalence augmente avec le vieillissement de la 
population.1,2 
             Il s'agit d'une maladie chronique surnoise dont les symptômes se 
manifestent uniquement lors des stades avancés et qui peuvent mener à la 
cécité. Présentement, le  seul moyen possible d’arrêter la progression du 
glaucome au stade initial est de diminuer la pression intra-oculaire (PIO). Les 
analogues de prostaglandines (APG) topiques sont fréquemment utilisées 
comme traitement de première ligne. Cependant, la recherche démontre que 
cette classe de médicaments peut changer certaines propriétés de la cornée, et 
possiblement influencer la mesure de la PIO.3 
Objectif: 
  À déterminer si l'utilisation d'APG affecte les propriétés biomécaniques de 
la cornée. La conclusion sera basée sur l'analyse intégrée des résultats obtenus 
de l'analyseur Reichert oculaire Réponse (ORA), la tonométrie par applanation 
de Goldmann (TAG) et la pachymétrie ultrasonographique. Le deuxième objectif 
potentiel de cette étude est de déterminer la corrélation, le cas échéant, entre les 
propriétés biomécaniques de la cornée, l'épaisseur de la cornée centrale (ECC) 
et la PIO chez les patients subissant un traitement d’APG topique. 
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L'hypothèse principale de cette étude est que l’APG influence les 
propriétés de la cornée telles que l'épaisseur centrale, l'élasticité et la résistance. 
Patients et méthodes : 
  Soixante-dix yeux de 35 patients, âgés de 50-85 ans, atteints de 
glaucome à angle ouvert (GAO) et traités avec APG topique ont été examinés. 
Seulement les sujets avec une réfraction manifeste entre -6,00 D et +4,25 D ont 
été inclus. Les critères d'exclusion sont: patients avec n'importe quelle autre 
maladie de la cornée de l’œil, telles que la dystrophie endothéliale de Fuch’s et  
kératocône, ou tout antécédent de traumatisme ou d'une chirurgie de la cornée, 
ainsi que le port de lentilles de contact. Nous avons demandé aux patients 
atteints du glaucome qui ont des paramètres stables et qui utilisent l’APG dans 
les deux yeux de cesser l’APG dans l'œil moins affecté par la PIO, et de 
continuer l’utilisation d’APG dans l'œil contralatéral. Le meilleur œil est défini 
comme celui avec moins de dommage sur le champ visuel (CV)  (déviation 
moyenne (DM), le moins négatif) ou une PIO maximale historique plus basse si 
la DM est égale ou encore celui avec plus de dommage sur la tomographie par 
cohérence optique (TCO, Cirrus, CA) ou la tomographie confocale par balayage 
laser (HRT, Heidelberg, Allemagne). Toutes les mesures ont été prises avant la 
cessation d’APG et répétées 6 semaines après l’arrêt. Les patients ont ensuite 
recommencé l’utilisation d’APG et toutes les mesures ont été répétées encore 
une fois après une période supplémentaire de 6 semaines. Après commencer ou 
de changer le traitement du glaucome, le patient doit être vu environ 4-6 
semaines plus tard pour évaluer l'efficacité de la goutte.4 Pour cette raison, on 
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été décidé d'utiliser 6 semaines d'intervalle. Toutes les mesures ont été 
effectuées à l’institut du glaucome de Montréal par le même technicien, avec le 
même équipement et à la même heure de la journée. L'œil contralatéral a servi 
comme œil contrôle pour les analyses statistiques. La tonométrie par applanation 
de Goldmann a été utilisée pour mesurer la PIO, la pachymétrie 
ultrasonographique pour mesurer l'ECC, et l’ORA pour mesurer les propriétés 
biomécaniques de la cornée, incluant l'hystérèse cornéenne (HC).  
L’hypothèse de l'absence d'effet de l'arrêt de l’APG sur les propriétés 
biomécaniques a été examiné par un modèle linéaire à effets mixtes en utilisant 
le logiciel statistique R. Les effets aléatoires ont été définies à deux niveaux: le 
patient (niveau 1) et l'œil de chaque patient (niveau 2). Les effets aléatoires ont 
été ajoutés au modèle pour tenir compte de la variance intra-individuelle. L’âge a 
également été inclus dans le modèle comme variable. Les contrastes entre les 
yeux et les temps ont été estimés en utilisant les valeurs p ajustées pour 
contrôler les taux d'erreur internes de la famille en utilisant multcomp paquet 
dans R. 
Résultats: 
  Une augmentation statistiquement significative due l 'HC a été trouvée 
entre les visites 1 (sur APG) et 2 (aucun APG) dans les yeux de l'étude, avec 
une moyenne (±erreur standard) des valeurs de 8,98 ± 0,29 mmHg et 10,35 ± 
0,29 mmHg, respectivement, correspondant à une augmentation moyenne de 
1,37 ± 0,18 mmHg (p <0,001). Une réduction significative de 1,25 ± 0,18 mmHg 
(p <0,001) a été observée entre les visites 2 et 3, avec une valeur moyenne HC 
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finale de 9,09 ± 0,29 mmHg. En outre, une différence statistiquement significative 
entre l’oeil d’étude et le contrôle n'a été observée que lors de la visite 2 (1,01 ± 
0,23 mmHg, p <0,001) et non lors des visites 1 et 3.  
          Une augmentation statistiquement significative du facteur de résistance 
conréen (FRC) a été trouvée entre les visites 1 et 2 dans les yeux de l'étude, 
avec des valeurs moyennes de 10,23 ± 0,34 mmHg et 11,71 ± 0,34 mmHg, 
respectivement. Le FRC a ensuite été réduit de 1,90 ± 0,21 mmHg (p <0,001) 
entre les visites 2 et 3, avec une valeur moyenne FRC finale de 9,81 ± 0,34 
mmHg. Une différence statistiquement significative entre l’oeil d’étude et le 
contrôle n'a été observée que lors de la visite 2 (1,46 ± 0,23 mmHg, p <0,001). 
Une augmentation statistiquement significative de l'ECC a été trouvée 
entre les visites 1 et 2 dans les yeux de l'étude, avec des valeurs moyennes de 
541,83 ± 7,27 µm et 551,91 ± 7,27 µm, respectivement, ce qui correspond à une 
augmentation moyenne de 10,09 ± 0,94 µm (p <0,001). L'ECC a ensuite diminué 
de 9,40 ± 0,94 µm (p <0,001) entre les visites 2 et 3, avec une valeur moyenne 
finale de 542,51 ± 7,27 µm. Une différence entre l’étude et le contrôle des yeux 
n'a été enregistré que lors de la visite 2 (11,26 ± 1,79 µm, p <0,001).  
            De même, on a observé une augmentation significative de la PIO entre 
les visites 1 et 2 dans les yeux de l'étude, avec des valeurs moyennes de 15,37 
± 0,54 mmHg et 18,37 ± 0,54 mmHg, respectivement, ce qui correspond à une 
augmentation moyenne de 3,0 ± 0,49 mmHg (p <0,001). Une réduction 
significative de 2,83 ± 0,49 mmHg (p <0,001) a été observée entre les visites 2 et 
3, avec une valeur moyenne de la PIO finale de 15,54 ± 0,54 mmHg. L’oeil de 
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contrôle et d’étude ne différaient que lors de la visite 2 (1,91 ± 0,49 mmHg, p 
<0,001), ce qui confirme l'efficacité du traitement de l’APG.  
           Lors de la visite 1, le biais de la PIO (PIOcc - PIO Goldmann) était 
similaire dans les deux groupes avec des valeurs moyennes de 4,1 ± 0,54 
mmHg dans les yeux de contrôles et de 4,8 ± 0,54 mmHg dans les yeux 
d’études. Lors de la visite 2, après un lavage de 6 semaines d’APG, le biais de la 
PIO dans l'œil testé a été réduit à 1,6 ± 0,54 mmHg (p <0,001), ce qui signifie 
que la sous-estimation de la PIO par TAG était significativement moins dans la 
visite 2 que de la visite 1. La différence en biais PIO moyenne entre l'étude et le 
contrôle des yeux lors de la visite 2, en revanche, n'a pas atteint la signification 
statistique (p = 0,124). On a observé une augmentation peu significative de 1,53 
± 0,60 mmHg (p = 0,055) entre les visites 2 et 3 dans les yeux de l'étude, avec 
une valeur de polarisation finale de la PIO moyenne de 3,10 ± 0,54 mmHg dans 
les yeux d'études et de 2,8 ± 0,54 mmHg dans les yeux de contrôles. 
Nous avons ensuite cherché à déterminer si une faible HC a été associée 
à un stade de glaucome plus avancé chez nos patients atteints du glaucome à 
angle ouvert traités avec l’APG. Lorsque l'on considère tous les yeux sur l’APG 
au moment de la première visite, aucune association n'a été trouvée entre les 
dommages sur le CV et l'HC. 
          Cependant, si l'on considère seulement les yeux avec un glaucome plus 
avancé, une corrélation positive significative a été observée entre la DM et l'HC 
(B = 0,65, p = 0,003). Une HC inférieure a été associé à une valeur de DM de 
champ visuelle plus négative et donc plus de dommages liés au glaucome. 
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Conclusions : 
  Les  prostaglandines topiques affectent les propriétés biomécaniques de 
la cornée. Ils réduisent l'hystérèse cornéenne, le facteur de résistance cornéen et 
l'épaisseur centrale de la cornée. On doit tenir compte de ces changements lors 
de l'évaluation des effets d’APG sur la PIO. Plus de recherche devrait être 
menées pour confirmer nos résultats. De plus, d’autres études pourraient être 
réalisées en utilisant des médicaments qui diminuent la PIO sans influencer les 
propriétés biomécaniques de la cornée ou à l'aide de tonomètre dynamique de 
Pascal ou similaire qui ne dépend pas des propriétés biomécaniques de la 
cornée. En ce qui concerne l'interaction entre les dommages de glaucome et 
l'hystérésis de la cornée, nous pouvons conclure qu' une HC inférieure a été 
associé à une valeur de DM de CV plus négative. 
 
Mots Clés 
glaucome - analogues de prostaglandines - hystérèse cornéenne – l’épaisseur 
de la cornée centrale - la pression intraoculaire - propriétés biomécaniques de la 
cornée. 
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ABSTRACT 
Rationale: 
Glaucoma is a chronic disease that causes a gradual loss of vision due to 
progressive damage to the optic nerve.  It is widespread in the world and causes 
blindness in about seven million people. In addition, it affects more than 400,000 
Canadians and its prevalence is increasing with the aging of the population.1, 2 
         Glaucoma becomes symptomatic only in the more advanced stages of the 
disease, and currently, the goal of treatment is to halt the progression of the 
disease by lowering the intra-ocular pressure (IOP). Topical prostaglandin 
analogs (PGA) are currently the first line treatment, however research has shown 
that this class of medications may change certain properties of the cornea, and 
hence the measurement of IOP.3 
Aim: 
To determine whether the use of topical prostaglandin analogs (PGA) 
affects the biomechanical properties of the cornea. The conclusion will be based 
on the integrated analysis of the data collected from the Reichert Ocular 
Response Analyzer (ORA), Goldmann tonometry and ultrasound pachymetry. 
The second potential aim of this study is to determine the correlations, if any, 
between the biomechanical properties of cornea, the Central Corneal Thickness 
(CCT) and IOP in patients undergoing topical PGA treatment. 
The main hypothesis of this study is that the PGA drops influence the 
properties of the cornea such as central thickness, elasticity and resistance.   
Patients and Methods: 
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In this study, seventy eyes of 35 patients, aged 50 - 85 years, with open angle 
glaucoma (OAG) and treated with topical PGA were examined. Only subjects 
with a manifest refraction between -6.00 D and +4.25 D were included. Exclusion 
criteria included patients with any other corneal eye disease, such as Fuch’s 
endothelial dystrophy or keratoconus, or any past history of corneal trauma or 
surgery. Contact lens wearers were also excluded. Patients with stable glaucoma 
parameters who were using topical PGA in both eyes prior to the start of the 
study were asked to discontinue the PGA in the best eye and to continue the 
application of PGA to the contralateral eye. The "best" eye, representing the eye 
with the least amount of glaucoma-related damage, was selected based on the 
results of the Humphrey Visual Field (HFA, Carl Zeiss Meditec, Inc., Dublin, CA), 
Heidelberg Retinal Tomography (HRT II, Heidelberg Engineering GmbH, 
Heidelberg, Germany), Optical Coherence Tomography (CIRRUS HD-OCT, Carl 
Zeiss Meditec, Inc., Dublin, CA)  and maximum IOP. The contralateral eye 
served as a control for statistical analyses. Corneal measurements were taken 
before PGA cessation and repeated 6 weeks after cessation. Patients then 
restarted the use of PGA and all measurements were repeated once more after 
an additional 6 weeks. After starting or changing glaucoma treatment the patient 
should be seen approximately 4-6 weeks later to assess efficacy of the drop.4 
For this reason it was decided to use 6 weeks interval. All measurements were 
performed at The Montreal Glaucoma Institute by the same trained technician, 
with the same equipment and at the same time of day. Goldmann applanation 
tonometry was used to measure the patient’s intraocular pressure (IOP), 
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ultrasound pachymetry was used to measure central corneal thickness (CCT) 
and the ORA provided the measurements of the corneal biomechanical 
properties, including corneal hysteresis (CH). 
The hypothesis of no effect regarding the discontinuation of PGA on the 
biomechanical properties was examined by a linear mixed-effect model using the 
nlme package in R. Random-effects was defined on two levels: the patient (level-
1) and the eye within each patient (level-2). Those random-effects were added to 
the model to account for the intra-individual variance due to the repeated-
measure design. Age was also included in the model as a covariate. Contrasts 
between the eyes and times were estimated using adjusted p-values to control 
for familywise error rate using multcomp package in R. 
Results:  
A statistically significant increase in CH was found between Visit 1 (on 
PGA) and Visit 2 (no PGA) in the study eyes, with mean (±Standard Error) values 
of 8.98 ± 0.29 mmHg and 10.35 ± 0.29 mmHg, respectively, corresponding to a 
mean increase of 1.37 ± 0.18 mmHg (p < 0.001). A significant reduction of 1.25 ± 
0.18 mmHg (p < 0.001) was also observed between Visits 2 and 3, with a final 
mean CH value of 9.09 ± 0.29 mmHg. In addition, a statistically significant 
difference between the study and control eyes was only observed at Visit 2 (1.01 
± 0.23 mmHg; p < 0.001) and not at Visits 1 and 3.  
A statistically significant increase in Corneal Resistance Factor (CRF) was 
found between Visits 1 and 2 in the study eyes, with mean values of 10.23 ± 0.34 
mmHg and 11.71 ± 0.34 mmHg, respectively. CRF was then reduced by 1.90 ± 
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0.21 mmHg (p < 0.001) between Visits 2 and 3, with a final mean CRF value of 
9.81 ± 0.34 mmHg. A statistically significant difference between the study and 
control eyes was only observed at Visit 2 (1.46 ± 0.23 mmHg; p < 0.001).   
A statistically significant increase in CCT was found between Visits 1 and 
2 in the study eyes, with mean values of 541.83 ± 7.27 µm and 551.91 ± 7.27 µm 
respectively, corresponding to a mean increase of 10.09 ± 0.94 µm (p < 0.001). 
CCT then decreased by 9.40 ± 0.94 µm (p < 0.001) between Visits 2 and 3, with 
a final mean value of 542.51 ± 7.27 µm. A difference between the study and 
control eyes was only recorded at Visit 2 (11.26 ± 1.79 µm; p < 0.001).  
Similarly, a significant increase in IOP was observed between Visits 1 and 
2 in the study eyes, with mean values of 15.37 ± 0.54 mmHg and 18.37 ± 0.54 
mmHg respectively, corresponding to a mean increase of 3.0 ± 0.49 mmHg (p < 
0.001). A significant reduction of 2.83 ± 0.49 mmHg (p < 0.001) was observed 
between Visits 2 and 3, with a final mean IOP value of 15.54 ± 0.54 mmHg. The 
control and study eyes only differed at Visit 2 (1.91 ± 0.49 mmHg; p < 0.001), 
confirming the effectiveness of PGA treatment.  
At Visit 1, the IOP bias (IOPcc – Goldmann IOP) was similar in both 
groups, all eyes at that time being on long term PGA medication, with mean 
values of 4.1 ± 0.54 mmHg in the control eyes and 4.8 ± 0.54 mmHg in the study 
eyes. At Visit 2, after a 6 week washout of PGAs, the IOP bias in the tested eye 
was reduced to 1.6 ± 0.54 mmHg (p<0.001), meaning that underestimation of 
IOP by Goldmann tonometry was significantly less than at Visit 1. The difference 
in mean IOP bias between the study and control eyes at Visit 2, however, did not 
 
 
xi 
 
reach statistical significance (p= 0.124).  A marginally significant increase of 1.53 
± 0.60 mmHg (p = 0.055) was observed between Visits 2 and 3 in the study eyes, 
with a final mean IOP bias value of 3.10 ± 0.54 mmHg in the study eyes and 2.8 
± 0.54 mmHg in the control eyes.  
We then tried to determine if a low CH was associated with signs of more 
severe glaucoma progression among our open-angle glaucoma patients treated 
with PGA. When considering all eyes on PGA at the time of the first Visit, no 
association was found between VF damage and CH. However, when considering 
only eyes with more advanced glaucoma, a significant positive correlation was 
observed between VF MD and CH (B = 0.65; p = 0.003). A lower CH was 
associated with a more negative visual field MD value and thus greater 
glaucoma-related damage. 
Conclusions:  
Topical prostaglandin analogs reduce CH, CRF, CCT and IOP in 
glaucomatous eyes. The changes in CH and CCT influence the measurement of 
IOP, and therefore, these changes should be taken into account when evaluating 
IOP lowering response to PGA medications. To discern an interaction between 
IOP and corneal hysteresis, further research should be conducted with 
intraocular pressure control. It can be achieved by using systemic medications 
that decrease IOP and do not influence biomechanical properties. It can also be 
achieved by using Pascal dynamic contour tonometry or a similar tonometer that 
does not depend on the biomechanical properties of the cornea.  
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Regarding the interaction between severity of glaucoma damage and corneal 
hysteresis, it was demonstrated that a lower CH was associated with a more 
negative visual field MD value. 
 Key Words 
glaucoma – prostaglandin analogs – corneal hysteresis – central corneal 
thickness – intraocular pressure – biomechanical properties of the cornea. 
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Introduction 
Over the last hundred years, questions concerning the diagnosis and treatment 
of glaucoma have surfaced. It has been estimated that glaucoma affects sixty-
seven million people worldwide, of whom seven million develop blindness. 
400,000 Canadians suffer from this disease of the optic nerve and its prevalence 
is increasing with time.1,2 Due to the evolution of technology, early diagnosis and 
appropriate treatment for glaucoma are now possible; however, a “completely 
cure” treatment for the present optic neuropathy does not currently exist. The 
search for the most effective treatment for glaucoma as well as for the most 
informative and predictive risk factors is ongoing.  
Previously, intraocular pressure (IOP) was considered the most valuable and 
informative risk factor and diagnosis for glaucoma. In addition, development of 
the disease resulted in a significant deviation of IOP from the normal range.  In 
present times, more and more researchers are paying close attention to other 
potential risk factors, diagnoses and outcomes, including the measurements of 
corneal thickness and corneal biomechanical properties. Note that these factors 
have a greater contribution to the development and progression of glaucoma 
than IOP itself. The explanation behind the importance of the properties and 
structure of the cornea in glaucoma is presented in the methodology of diagnosis 
and treatment. 
The cornea can be thought of as the window of the eye. It can be used in order to 
observe events occurring within the eyeball, to determine the intraocular pressure 
and to administer medication to the eye. During the measurement of intraocular 
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pressure, the cornea is flattened or applanated. The properties and structure of 
the cornea have an impact on the applanation event as a thicker and stiffer 
cornea requires a greater applied force to achieve applanation compared to a 
thinner and weaker cornea.5 Thus, corneal properties and structure influence IOP 
measurements. The administration of eye drops, such as Prostaglandin Analogs 
(PGA), directly onto the cornea can also affect its structure and properties.6-9 On 
the other hand, the cornea can influence drop action and effectiveness.10-22 
This study was conducted to better understand the association between the 
corneal biomechanical properties and the treatment, diagnosis and outcome of 
glaucoma.  
Research Objectives and Study Design 
Objectives:  
The primary objective is to determine whether the use of topical prostaglandin 
analog medication affects biomechanical properties of cornea. The conclusion 
will be based on the integrated analysis of the results obtained from the Reichert 
Ocular Response Analyzer (ORA), Goldmann tonometer and ultrasound 
pachymeter.  
The secondary aim of this study is to determine the associations between the 
corneal biomechanical properties, central corneal thickness (CCT) and 
intraocular pressure (IOP) in patients undergoing topical PGA medication 
treatment. 
Hypothesis:  
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PGA drops influence the central corneal thickness and corneal biomechanical 
properties including corneal hysteresis, elasticity and resistance. 
Study Design: 
A. Patients 
Thirty five patients (seventy eyes) between the ages of 50 and 85 years with 
open angle glaucoma (OAG) treated with topical PGA medications were recruited 
from the glaucoma clinics of the Montreal Glaucoma Institute. One of the 
patient’s eyes served as the experimental eye, while the contralateral eye served 
as the control for statistical analyses.   
B. Inclusion Criteria and Patient Definitions 
Recruited patients with OAG had gonioscopically open angles and a manifest 
refraction between -6.00 D and +4.25 D. Early glaucoma is arbitrarily defined as 
a mean defect of -2.00 to -6.00 db and moderate glaucoma as a mean defect of -
6.10 to -12.0 db. 
C. Exclusion Criteria 
Excluded individuals consisted of patients with any other corneal eye disease, 
such as Fuch’s endothelial dystrophy or keratoconus, or any past history of 
corneal trauma or surgery, including refractive surgery that may affect hysteresis 
measurements. Due to the fact that systemic medications may have an effect on 
the cornea and, therefore, alter the results of the study, patients using systemic 
prostaglandin pills, non-steroidal anti-inflammatory drugs or undergoing hormone 
replacement therapy were excluded. Contact lens wearers and patients with 
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uncontrolled glaucoma or far advanced visual field (VF) damage were also 
excluded.  
D. Study Procedures  
Following informed consent, patients undergoing topical PGA treatment in both 
eyes were asked to discontinue the PGA in their best eye (less damage on VF – 
better MD or lower max IOP if MD equal) and to continue the administration of 
PGA in the contralateral eye. Corneal measurements were taken before PGA 
cessation (Time 1) and repeated 6 weeks after cessation (Time 2). Patients then 
restarted the application of PGA to the experimental eye and all measurements 
were repeated once more after an additional 6 weeks (Time 3). After starting or 
changing glaucoma treatment the patient should be seen approximately 4-6 
weeks later to assess efficacy of the drop.4 For this reason it was decided to use 
6 weeks interval.  All measurements were performed at the Montreal Glaucoma 
Institute by the same trained technician, with the same equipment and at the 
same time of day. 
E. Data Collection 
Goldmann applanation tonometry (Haag-Streit AG, Koeniz, Switzerland) is the 
gold standard for measuring IOP in glaucoma patients. IOP was measured with 
the same calibrated tonometer during the study. 
Central Corneal Thickness (CCT) was measured by ultrasound pachymetry 
(DGH Technology, INC, Exton, PA, USA) and the average of three 
measurements was recorded.   
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The Ocular Response Analyzer (ORA) (Reichert, INC, Depew, NY, USA) utilizes 
a dynamic bi-directional applanation process to measure the biomechanical 
properties of cornea and the IOP of the eye. Using this device, biomechanical 
properties, including Corneal Hysteresis (CH), Corneal Resistance Factor (CRF), 
Corneal-Compensated Intraocular Pressure (IOPcc) and Goldmann-Correlated 
Pressure (IOPg), can be measured. The ORA was used to classify various 
corneal conditions based on biomechanical tissue properties, rather than 
geometrical measurements. 
The ORA utilizes a rapid air pulse to apply force to the cornea. An advanced 
electro-optical system monitors corneal deformation. A precisely-metered 
collimated-air-pulse causes the cornea to move inwards into slight concavity. 
Milliseconds after applanation, the air pump shuts off and the pressure gradually 
declines. As the pressure decreases, the cornea first passes through an 
applanated state before resuming its original curved structure. The applanation 
detection system monitors the cornea throughout the entire process, and two 
independent pressure values are derived from the INWARD and OUTWARD 
applanation events. The difference between these two pressure values is 
Corneal Hysteresis (CH). The CH is a measure of viscous damping in the cornea. 
The ability to measure this effect is the key to understanding the biomechanical 
properties of the cornea and their influence on the IOP measurement process. 
The normal value of CH is around 11.00 – 12.00 mmHg. 23 
The ORA was used for the measurements of CH (like a value of corneal 
biomechanical properties in general) and to verify the IOP. Four ORA 
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measurements were taken per eye and the mean value was recorded. The same 
ORA was used for all of the patients during the study. 
The CH measurement also provides a basis for two additional new parameters: 
IOPcc and CRF. IOPcc is an IOP measurement that utilizes the new information 
provided by the CH measurement to provide an IOP value that is less affected by 
corneal properties than other methods of tonometry, such as GAT. CRF is 
measurement of the cumulative effects of both the viscous and elastic resistance 
encountered by air jet while deforming the cornea. The normal value of CRF is 
around 10.00 – 11.00 mmHg.23 
All of the necessary equipment needed for this research was calibrated before 
the start and during the project to avoid imprecise measurements. 
F. Data Management 
Baseline and follow-up data was entered into an Excel spreadsheet. Statistical 
analyses were performed using the appropriate tests. 
G. Statistical Analysis  
The hypothesis of no effect regarding the discontinuation of PGA on the 
biomechanical properties was examined by a linear mixed-effect model using the 
nlme package in R. Random-effects was defined on two levels: the patient (level-
1) and the eye within each patient (level-2). Those random-effects were added to 
the model to account for the intra-individual variance due to the repeated-
measure design. Age was also included in the model as a covariate. Contrasts 
between the eyes and times were estimated using adjusted p-values to control 
for familywise error rate using multcomp package in R.24 
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H. Ethical Considerations 
The approval was obtained by the ethics committee of Maisonneuve-Rosemont 
Hospital. Prospective candidates were thoroughly informed of the protocol and 
had the opportunity to have any questions answered before being asked for 
informed consent. Each patient was given a code and all data was masked to 
protect patient confidentiality. 
Ocular exams, IOP, pachymetry and ORA are part of standard care for human 
testing and pose minimal risk to subjects. These studies will contribute towards a 
better understanding of Glaucoma and, eventually, to better management.  
This study was conducted in accordance with research protocol and 
recommendation of the ethics commission. All ethical issues connected with this 
study were resolved in accordance with applicable law and ethical principles. 
 
 
  
 
 
 
 
 
 
Chapter I: The Normal Human Cornea 
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1.1   Anatomy of the Human Cornea 
The cornea is the anterior transparent connective tissue of the eye. It is 
responsible for protecting the eye from injury and infection. It also provides the 
majority (two thirds) of the total refractive power of the eye.25 
The cornea is comprised of five layers (see Figure 1): the outermost non-
keratinised stratified epithelium, Bowman’s layer, a highly ordered keratocyte-
populated collagenous stroma, Descemet’s membrane and the inner endothelium 
(a cellular monolayer). 
 
Figure 1: The human cornea in cross-section  
(from: http://www.stembook.org).  
 
 
In emmetropic adults, the average white-to-white diameter of the cornea is 11.5 
to 12.3 mm. The central corneal thickness ranges from 528 to 588 μm and 
gradually increases towards the periphery.26 
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1.1.1 Epithelium 
The corneal epithelium forms the first barrier separating the eye from the external 
environment. It is a stratified non-keratinized squamous epithelium containing 4 
to 6 cell layers (40 to 50 μm in thickness). These layers are divided from 
posterior to anterior into: basal, wing and superficial cells. Corneal epithelial 
lifespan is approximately 1 week. During that short period, the cells go through 
systematic involution, apoptosis and desquamation. This process leads to a 
complete renewal of the epithelium every week.27 The differentiated squamous 
cells have surface microvilli and occupy the outer 1–3 cell layers of the epithelium 
(Figure 2). The function of the microvilli is to increase cell surface area, forming a 
close association with the tear film. Highly resistant tight junctions between 
neighbouring cells form a protective barrier.10  
 
Figure 2: Corneal epithelial layers11 
 
The inner basal cells consist of a single layer of columnar cells (~20 μm tall). 
Their functions include the generation of new suprabasal cells, the secretion of 
 
 
10 
 
matrix factors and the regulation of the organisation of hemidesmonsomes and 
focal complexes to maintain attachment to the underlying basement membrane. 
They also secrete their basement membrane (0.05 μm in thickness) containing 
collagen type IV and laminin.11 These functions are believed to be important in 
mediating cell migration in response to epithelial injury.12  
1.1.2 Bowman’s Membrane 
Bowman’s membrane (10-15 μm in thickness) lies posterior to the basement 
membrane of the epithelium. It is not a true membrane as it is an acellular 
condensation of collagen fibers and proteoglycans of the anterior portion of the 
stroma. It does not exist in many mammals. In cases of injury, this membrane 
does not regenerate and forms a scar.11 
1.1.3 Stroma 
The stroma is a mesenchymal tissue derived from the neural crest. It constitutes 
85% to 90% of corneal thickness. The central stroma is thinner than the 
peripheral one, and the collagen fibers change their direction and run 
circumferentially when they arrive near the limbus.13  Stromal collagen fibers 
consist mainly of collagen types I and V to achieve their uniform diameter. 
Collagen types VI and XII bind other types of collagen fibers and help to maintain 
the regularity of the stromal structure. Keratan sulfate and chondroitin 
sulfate/dermatan sulfate, which make up the ground substance of the stroma, 
play a role in regulating the hydration state and the uniform structure of the 
stroma. 
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The transparency of the stroma is unique among other collagenous structures.  
The parallel arrangement of lamellae formed from heterodimeric complexes of 
type I and type V collagen fibers maintain transparency.14 The keratocytes 
(fibroblasts) located between the lamellae15 link to one another via dendritic 
processes16, producing crystalline proteins that also help maintain corneal 
transparency.17   
The corneal endothelium plays a critical role in maintaining the relatively 
dehydrated state of the stroma, thus preserving the precise organisation of the 
stromal collagen fibers. These collagen fibres are held in a uniform spacing 
pattern by proteoglycans.  
The posterior lamellae are more arranged and less rigid than the anterior ones. 
This biomechanical difference is translated clinically in a stromal edema that is 
more marked posteriorly, pushing on the Descemet’s membrane and creating 
Descemet folds.11  
1.1.4 Descemet’s Membrane 
The Descemet’s membrane (DM) rests on the innermost surface of the cornea. It 
acts as a basement membrane for the inner endothelial cell monolayer. The 
normal DM is composed of two layers (Figure 3): 
- Anterior banded layer: It is present in the eye of the fetus at five months of 
gestation. Its thickness is approximately 3 μm and it remains the same at all 
ages.18 
- Posterior nonbanded layer: It is secreted onto the posterior surface of the 
banded fetal portion after birth by the endothelial cells. Its thickness increases 
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significantly with age, averaging ~2 μm at 10 years of age and ~10 μm at 80 
years of age.19 
In healthy adults, the DM is composed of collagen type IV (dominant), VIII and 
XII, laminin, perlecan, nidogen-1, nidogen-2, netrin-4, vitronectin and 
fibronectin.18,20  These cells transport nutrients from the aqueous humour to the 
stroma. In addition, they pump out excess water and prevent corneal edema 
(swelling) by maintaining optimal hydration. 
 
Figure 3: Transmission electron microscopy (TEM) of Descemet’s 
membrane (DM) showing posterior stroma (S), anterior (A) and posterior (P) 
layers of normal DM, and endothelium (EN)11 
 
 
1.1.5 Endothelium 
Corneal specialists consider the endothelium as the soul of the cornea. 
At approximately the sixth week of gestation, corneal endothelial cells originating 
from the neural crest (neuroectoderm) migrate centrally from the rim of the optic 
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cup to form a monolayer of cubical cells.21  Over time, these cells flatten and start 
to secrete their basal membrane (DM).  
The DM fuses peripherally with the trabecular beams where the Schwalbe line 
defines the ending of DM and the beginning of the trabecular meshwork.11 
It appears as a uniform honeycomb-like mosaic with four to nine sides, about 
20μm in diameter and 250 μm² in cell area (Figure 4).  
The lateral membranes enclose a high density of Na+/ K+-ATPase pump sites. An 
individual endothelial cell contains a large number of oblong nuclei, numerous 
mitochondria, a rough endoplasmic reticulum (RER), and a prominent Golgi 
apparatus (indicating elevated levels of protein synthesis including enzymes, 
structural proteins and extracellular matrix (ECM) proteins) (Figure 4). 21, 11 
The central endothelial cell density decreases at an average rate of 0.6% per 
year in normal corneas.22 It was also found that there is no correlation between 
corneal thickness and endothelial cell density, cell area, coefficient of variation or 
cell shape.11 
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Figure 4: Specular microscopy photo of the normal corneal endothelium. 
Note the regular hexagonal pattern11 
 
1.2 Physiology of the Human Cornea 
1.2.1 Biomechanical Properties of the Cornea 
The human cornea is considered “the window” of the eye, enabling a professional 
to see the events occurring within the eye. The transparency of the cornea is one 
of several corneal properties, which vary according to the different corneal 
functions.  
The cornea consists primarily of collagen, a viscous and elastic material. The 
viscoelasticity provides a measure of corneal biomechanics and protects against 
mechanical and biological damages. The visco-elastic properties of the cornea 
reflect its ability to absorb the energy of the external force and bend during 
compression.5, 28  
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In clinics, the corneal viscoelasticity is used to verify intraocular pressure. During 
the measurement of intraocular pressure, the cornea is deformed. This 
deformation is determined by the interaction between the external force and the 
corneal visco-elastic properties. A greater deformation occurs in response to 
lower intraocular pressure; however it is also associated with a “weaker” and 
“softer” cornea. A smaller corneal deformation not only indicates a higher 
intraocular pressure but also that the cornea is “stiff” and “hard”.  
Corneal hysteresis (CH) is a corneal biomechanical property and it can be 
measured using the ocular response analyzer. 29 
 
 
 
 
  
 
 
 
 
Chapter II: Glaucoma 
 
 
 
 
 
 
  
 
 
17 
 
2.1   Anatomy and Definition of Glaucoma 
Glaucoma is the leading cause of irreversible blindness throughout the world1, 
affecting an estimated 67 million individuals of whom approximately 10 percent 
are bilaterally blind. It is also the second leading cause of blindness and visual 
handicap in Canada, affecting 1% of the Canadian population. 2 The prevalence 
of glaucoma rises dramatically with increasing age. In fact, it is known to rise 
exponentially after the age of 40.30 
Glaucoma is a chronic and generally bilateral but often asymmetrical eye 
disease. It is characterized by damage to the optic nerve that is usually caused 
by excessively high intraocular pressure (IOP).  
2.1.1 Anatomy of the Optic Nerve Head 
The optic nerve head (ONH), also known clinically as the optic disc or papilla, 
forms the exit point for retinal ganglion cell (RGC) axons through the scleral 
canal. It consists mainly of nerve fibers (1.2-1.5 million retinal ganglion cell 
axons), glial cells, extracellular matrix supporting tissue and vascular elements.31-
33 The ONH stands out from the neighboring peripapillary tissue by a scleral rim 
of connective tissue known as the border tissue of Eischnig.34 
The ONH is divided into four anatomical areas from front to back35-38:  
A. Surface nerve fiber layer: a continuous layer of retinal nerve fibers. It consists 
of non-myelinated axons of RGCs in transition from the surface of the retina to 
the neural component of the optic nerve.  
B. Prelaminar area: an area between the surface layer of nerve fibers and the 
lamina cribrosa at the level of the choroid and the outer retina. It consists of 
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nerve fibers arranged in bundles surrounded by glial tissue septa and astrocytes.  
C. Lamina cribrosa region: adjacent to the sclera and penetrates it. The lamina 
cribrosa region also provides substantive support to the optic nerve at the exit of 
the eye.  
D. Retrolaminar region: this region is located behind the lamina cribrosa. It is 
marked by the beginning of myelination of axons and surrounded by 
leptomeninges of the central nervous system. 
The differences between these four regions reflect the conditions in which axons  
pass through the ONH. These differences include myelination of axons posterior 
to lamina cribrosa, sources of blood supply, changes intraocular pressure and 
cerebrospinal fluid pressure. 
2.1.2 Anatomy of the Anterior Segment of Eyeball 
The anterior segment consists of the cornea, the anterior and posterior 
chambers, iris, lens and others (Figure 5).  
 
Figure 5. Anatomy of the eye 
(from: www.marineyes.com) 
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The angle of the anterior chamber (where the iris meets the cornea) plays a 
critical role in the pathophysiology of glaucoma. It consists of the ciliary body, 
scleral spur, trabeculae (system funnels for filtration of liquid) and Schwalbe line 
(Figure 6).  
 
Figure 6. Anatomy of anterior chamber 
(from: www.academy.org.uk) 
 
The iris is connected to the sclera via a mesh-like fibrillar structure called the 
trabecular meshwork or trabeculae.  The ciliary body produces a fluid that 
provides nutrients to the lens and cornea (two structures in anterior segment of 
the eye that do not have a blood supply). This fluid also flows around the lens, 
through the pupil of the iris, into the anterior chamber and then exits through the 
trabecular meshwork. Behind this meshwork lies a circumferential tubular 
structure called the canal of Schlemm. This canal is connected to the venous 
outflow of the eye through a series of interconnecting tubules called the collector 
channels (Figure 7). 39, 3  
 
 
20 
 
 
Figure 7. Anatomy of trabecular meshwork and intra-ocular fluid circulation  
(from: www.pharmacologydopt.blogspot.com) 
2.2 Pathophysiology of Glaucoma  
2.2.1 Types of Glaucoma 
Due to distinct anatomical and physiological features, specialists can distinguish 
the following types of glaucoma: open-angle glaucoma, closed-angle glaucoma, 
pigment dispersion syndrome, exfoliation syndrome, normal tension glaucoma, 
secondary glaucoma and others. 
Primary open angle glaucoma is by far the most common form of the disease in 
North America, affecting Caucasians and persons of African ancestry. Its 
incidence increases with age. Primary open angle glaucoma is defined as a 
chronic, generally bilateral, but also asymmetrical disease characterized by all of 
the following40: 
1. Evidence of glaucomatous optic nerve damage. 
2. Adult onset. 
3. Open normal-appearing anterior chamber angles. 
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4. Absence of known other causes of open angle glaucoma. 
2.2.2 Risk Factors for Glaucoma  
Previously, the measurement of intraocular pressure (IOP) was considered the 
most valuable and informative risk factor and diagnosis for glaucoma. In addition, 
development of the disease resulted in a significant deviation of IOP from the 
normal range.  In present times, more and more researchers have begun to pay 
close attention to other potential risk factors, diagnoses and outcomes, including 
the measurements of corneal thickness and corneal biomechanical properties. 
Note that these factors have a greater contribution to the development and 
progression of glaucoma than IOP itself.3 
2.3 Methods of Diagnosis of Glaucoma 
Diagnosing a patient with glaucoma is a difficult task for physicians. Even though  
additional tools for diagnosing glaucoma were invented, such as the Heidelberg 
Retinal Tomograph (HRT) and Optical Coherence Tomography (OCT), the 
primary methods of diagnosis are still IOP measurement, ophthalmoscopy of the 
optic disc and visual field testing. 
Due to the discovery of additional risk factors, the measurements of central 
corneal thickness and corneal biomechanical properties have been integrated 
into routine practice.  
Let's look at these methods of diagnosis in more detail. 
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The Humphrey Visual Field test is used to define visual field defects, which are 
characteristic of glaucoma. This is a useful tool for diagnosis and glaucoma 
follow-up.  
Ophthalmoscopy of the optic disc and retina, performed by ophthalmologist, is 
used to verify optic nerve cupping and changes in retinal structures.  
Heidelberg Retinal Tomograph (HRT) is a confocal laser scanning system used 
for acquisition and analysis of three-dimensional images of the posterior segment 
of the eye. HRT measures linear Cup/Disk ratio, Rim area and RNFL thickness. It 
can be used for diagnosis as well as for glaucoma follow-up.  
Optical Coherence Tomography (OCT) is a non-invasive imaging test that uses 
light waves to take cross-section pictures of the retina and optic nerve disk. OCT 
can measure Cup/Disk ratio, Rim area, RNFL thickness and ganglion cells 
analysis. It can be used for diagnosis as well as for glaucoma follow-up. 
Goldmann applanation tonometry is the gold standard for measuring IOP in 
glaucoma patients. It can be used for the diagnosis of glaucoma and pressure 
control.  A special disinfected prism is mounted on the head of the tonometer and 
then placed against the cornea. The examiner then uses a cobalt blue filter to 
view two green semi circles. The force applied to the tonometer head, which 
flattens the cornea, is used to measure IOP. Like all non-invasive methods, it is 
inherently imprecise. 
2.3.1 Measurements of Biomechanical Properties of the Cornea 
Central Corneal Thickness (CCT) can be measured by ultrasound pachymetry.  It 
has recently been identified as a risk factor for glaucoma development and is 
considered during the correction of IOP measurements and glaucoma follow-up.  
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According to measurements of CCT and tonometery presented in Figure 8, the 
patient’s true pressure can be calculated. Thinner corneas are associated with 
higher IOP values and vice versa. 
 
Figure 8. Correction values of IOP according to corneal thickness 
(from: www.emedicine.medscape.com) 
 
The biomechanical properties of the cornea are measured using the ocular 
response analyzer (ORA). This device measures the corneal hysteresis, a newly 
discovered risk factor for glaucoma development that is also analyzed during 
glaucoma follow-up.  
The ORA utilizes a dynamic bi-directional applanation process to measure the 
biomechanical properties of cornea and the IOP. A rapid air pulse applies force to 
the cornea and an advanced electro-optical system monitors corneal 
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deformation. A precisely-metered collimated-air-pulse pushes the cornea 
inwards, past a flat state and into a slight concavity. Milliseconds after 
applanation, the air pump shuts off and the pressure gradually declines. As the 
pressure decreases, the cornea first passes through an applanated state before 
resuming its original curved structure. The applanation detection system monitors 
the corneal movement throughout the entire process. Two separate pressure 
values are derived from the INWARD and OUTWARD applanation events. The 
difference between these two pressure values is termed Corneal Hysteresis 
(CH). The CH is a measure of viscous damping in the cornea. The ability to 
measure this effect is the key to understanding the biomechanical properties of 
the cornea and their influence on the IOP measurement process. The normal 
value of CH is around 11.00 – 12.00 mmHg. 23  
The ORA can be used to classify various corneal conditions based on 
biomechanical tissue properties rather than geometrical measurements. The 
ORA enables the measurements of corneal biomechanical properties (Figure 9) 
such us Corneal Hysteresis (CH), Corneal Resistance Factor (CRF), Corneal-
Compensated Intraocular Pressure (IOPcc) and Goldmann-Correlated Pressure 
(IOPg).29 
The CH measurement also provides a basis for two additional new parameters: 
IOPcc and CRF. IOPcc is an IOP measurement that utilizes the new information 
provided by the CH measurement to provide an IOP value that is less affected by 
corneal properties than other methods of tonometry, such as GAT. CRF is 
measurement of the cumulative effects of both the viscous and elastic resistance 
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encountered by air jet while deforming the cornea. The normal value of CRF is 
around 10.00 – 11.00 mmHg.23 
  
Figure 9. The ocular response analyzer measurement curve 
(from: www.reichert.com) 
 
The biomechanical properties of the cornea play an extraordinary role in 
diagnosis of glaucoma as well as in course of the disease and prognosis. The 
individual with low CCT and CH has a greater risk of developing glaucoma. Low 
CCT and CH are also associated with a more rapid progression of the disease.  
2.4 Treatment of Glaucoma  
The treatments for glaucoma can be classified as medical, laser or surgical. 
Laser and surgical treatments are usually used for patients with advanced stages 
of glaucoma as well as for those that do not respond to medication. Medication is 
administered in the form of drops and different types of eye drops have different 
functions. There are those that reduce the production of intra-ocular fluid (B-
blockers and Brinzolamide), drops that improve anterior outflow tracts 
(Pilocarpine) and drops that improve anterior and posterior outflow paths 
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(prostaglandin analogs (PGA)). The search for the most effective treatment for 
glaucoma, defined as the best method to stabilize the circulation of intraocular 
fluid, is ongoing.  
2.4.1 Topical PGA Medications, Mechanism of Actions 
Topical PGAs are currently the first choice of intraocular pressure reducing 
medication. Among them are several distinguished groups of drugs such as 
Bimatoprost, Latanoprost, Travoprost and Tafluprost. The mechanism of action of 
these drops is similar; however, there are some differences. 
Prostaglandin analogs reduce pressure inside the eye (IOP) by increasing the 
uveoscleral outflow, thus increasing the removal of the aqueous humor from the 
eye. The exact mechanism for this is unknown. Meanwhile, one well-studied 
mechanism by which PGA increases the uveoscleral outflow involves the 
regulation of matrix metalloproteinases and remodeling of extracellular matrix. 
Other proposed mechanisms include widening of the connective tissue-filled 
spaces and changes in the shape of cells. The final steps of all these 
mechanisms alter the permeability of the tissues of the outflow pathways leading 
to changes in outflow resistance and/or outflow rates. Prostaglandin receptors 
and their associated mRNAs have been located in the trabecular meshwork, 
ciliary muscle, and sclera, providing evidence that endogenous prostaglandins 
have a functional role in aqueous humor drainage.6 In addition, it was recently 
found that the same PGA receptors are also found in the cornea as well.41-48,7-9 
This can explain the actions of PGA on corneal properties (Figure 10). 
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Figure 10: The action and interaction of PGA medication in the eye 
 PGA medications mechanism of action and interaction in the eye 
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3.3 Abstract 
Purpose: To determine the influence of prostaglandin analog (PGA) medication 
on corneal biomechanical properties in patients undergoing PGA treatment for 
open-angle glaucoma.  
Participants: Seventy eyes of 35 patients, aged 50 to 85 years, with open-angle 
glaucoma and undergoing topical PGA treatment were recruited for the study. 
One of the patient’s eyes served as the experimental eye, while the contralateral 
eye served as the control. 
Methods: From a treated baseline (Visit 1), patients discontinued the application 
of PGA in their "best" eye for a period of 6 weeks (Visit 2). Intraocular pressure 
(IOP), corneal hysteresis (CH) and central corneal thickness (CCT) were 
measured and recorded. Following Visit 2, patients resumed the application of 
PGA to the experimental eye for a final 6-week period and the measurements 
were repeated (Visit 3). 
Main Outcome Measures: IOP, CH and CCT were measured using a Goldmann 
applanation tonometer, Reichert Ocular Response Analyzer and ultrasound 
pachymetry. 
Results: Mean CH (±Standard Error) decreased from 10.35 ± 0.28 mmHg to 
8.98 ± 0.28 mmHg following the PGA treatment in the experimental eye. CCT, 
corneal resistance factor (CRF) and Goldmann IOP increased by 10.09 ± 0.94 
µm (p < 0.001), 1.49 ± 0.21 mmHg (p < 0.001) and 3.0 ± 0.49 mmHg (p < 0.001) 
respectively, after PGA cessation. The data suggests that patients undergoing 
PGA therapy are subject to greater underestimation of IOP as measured by the 
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Goldmann applanation tonometer.  
Conclusion: Topical PGA reduces CH, CRF, CCT and IOP in patients suffering 
from open-angle glaucoma. Deviations of CH and CCT values from the normal 
range contribute to the false IOP readings made by the Goldmann applanation 
tonometer and should be considered when measuring IOP to monitor the 
response to treatment.  
3.4 Introduction 
Glaucoma affects approximately 67 million people worldwide, of whom seven 
million develop blindness. Despite significant progress in pharmacotherapy, laser 
technology, and surgical techniques, the treatment of glaucoma remains a 
challenge.1 Early diagnosis and accurate assessment of glaucoma progression 
and response to treatment are essential in order to adjust treatment and minimize 
the risk of permanent blindness.  
While intraocular pressure (IOP) has long been considered the most valuable 
indicator of glaucoma progression, closer attention is now paid to other potential 
risk factors susceptible to influence diagnosis and outcome of glaucoma such as 
corneal thickness and corneal biomechanical properties.3  
Corneal Hysteresis (CH) and Corneal Resistance Factor (CRF) are classified as 
corneal biomechanical properties. CH represents the viscous damping occurring 
within the cornea in response to an applied force. Thus, a low CH reflects a lack 
of energy absorption. CRF, on the other hand, is a measure of corneal rigidity 
dependent on the elastic and viscous materials of the cornea. A reduction in CRF 
signifies a lack of resistance to deformation.49 
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The cornea is primarily composed of collagen, a documented viscoelastic 
material. During Goldmann applanation tonometry (GAT), the cornea is flattened 
or applanated. Applanation is affected by the biomechanical properties of the 
cornea as a thicker and stiffer cornea requires a greater applied force to achieve 
applanation compared to a thinner and weaker cornea. Corneal hysteresis (CH) 
represents the viscoelasticity of the cornea. This biomechanical property is 
existent due to the collagen content and composition of the corneal extracellular 
matrix.50 
The objective of the study was to determine whether the use of topical PGA 
medication affects CH and CRF in eyes with open-angle glaucoma. 
3.5 Methods 
Patients 
Thirty five patients (seventy eyes) with bilateral open angle glaucoma on 
monotherapy with topical PGA medication in both eyes were recruited from the 
Montreal Glaucoma Institute, Montreal, QC, Canada. Exclusion criteria included 
any corneal disease (such as Fuchs’ endothelial dystrophy or keratoconus) or a 
past history of corneal trauma or surgery (including refractive surgery) that may 
affect hysteresis measurements. Contact lens wearers and patients with 
uncontrolled glaucoma or advanced visual field (VF) damage (mean defect < -
12.0 db) were excluded. Patients taking systemic prostaglandin medication, non-
steroidal anti-inflammatory drugs or undergoing hormone replacement therapy 
were also excluded from this study. Informed consent was acquired from all 
participants. The research protocol of this study adhered to the tenets of the 
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Declaration of Helsinki. It was approved by the Maisonneuve-Rosemont Hospital 
Ethics Committee (Montreal, QC, Canada) and all patients signed a research 
consent form.  
Study Procedures  
Consenting patients undergoing topical PGA treatment in both eyes were asked 
to discontinue the PGA in their best eye and to continue the administration of 
PGA in the contralateral eye. All measurements were taken before PGA 
cessation (Visit 1) and repeated 6 weeks after cessation (Visit 2). Patients then 
restarted the application of PGA to the experimental eye and all measurements 
were repeated once more after an additional 6 weeks (Visit 3). After starting or 
changing glaucoma treatment the patient should be seen approximately 4-6 
weeks later to assess efficacy of the drop.4 For this reason it was decided to use 
6 weeks interval. 
The best eye was selected based on less glaucoma damage. It was defined by 
the results of the Humphrey Visual Field (HFA, Carl Zeiss Meditec, Inc., Dublin, 
CA), Heidelberg Retinal Tomograph (HRT II, Heidelberg Engineering GmbH, 
Heidelberg, Germany) and Optical Coherence Tomography (CIRRUS HD-OCT, 
Carl Zeiss Meditec, Inc., Dublin, CA). The Humphrey Visual Field defines early 
glaucoma as a mean defect (MD) of -2.00 to -6.00 db, moderate glaucoma as a 
MD of -6.10 to -12.0 db and advanced as a MD less than -12.0 db. The Optical 
Coherence Tomography enables the identification of the better linear Cup/Disk 
ratio, Rim area, RNFL thickness and ganglion cells analysis between both of the 
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patient’s eyes. The lesser of the maximum IOP values recorded in each of the 
patient’s eyes also contributed to the selection of the best eye.  
Instruments 
The Ocular Response Analyzer (ORA) (Reichert, INC, Depew, NY) was used to 
assess the biomechanical properties of the cornea. This instrument utilizes a 
dynamic bi-directional applanation process to measure the biomechanical 
properties of the cornea and estimate IOP. A rapid air pulse applies force to the 
cornea and an advanced electro-optical system monitors corneal deformation. A 
precisely-metered collimated-air-pulse pushes the cornea inwards, past a flat 
state and into a slight concavity. Milliseconds after applanation, the air pump 
shuts off and the pressure gradually declines. As the pressure decreases, the 
cornea first passes through an applanated state before resuming its original 
curved structure. The applanation detection system monitors the corneal 
movement throughout the entire process. Two separate pressure values are 
derived from the INWARD and OUTWARD applanation events. The difference 
between these two pressure values is termed CH.29 This biomechanical property 
reflects corneal absorption and dissipation of the energy from an applied force.29 
Derived from the measurement of CH is the corneal resistance factor (CRF). 
CRF represents the cornea’s ability to resist deformation in the presence of an 
external force.49 
Goldmann applanation tonometry (Haag-Streit AG, Koeniz, Switzerland) is still 
recognized as the gold standard for measuring IOP in glaucoma patients and it 
was performed in all patients at all Visits. The ORA takes the CH and CRF 
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measurements into account to generate the corneal-compensated intraocular 
pressure (IOPcc) value, which is meant to be less affected by corneal 
biomechanical properties than the Goldmann-IOP.29,49  The IOP bias is estimated 
as the difference between IOPcc and Goldmann-IOP (IOPcc – Goldmann IOP).  
A positive bias value indicates that the IOPcc is larger than the Goldmann-IOP, 
meaning that Goldman tonometry underestimated IOP in comparison to the 
IOPcc. 
Four ORA measurements were taken per eye and the mean value was recorded 
for each parameter (CH, CRF and IOPcc). Central corneal thickness (CCT) was 
measured by ultrasound pachymetry (DGH Technology, INC, Exton, PA) and the 
average of three measurements was recorded. All study measurements were 
performed by the same trained observer (RM), with the same equipment and at 
the same time of day. All of the equipment needed for this research was 
calibrated prior to each use. 
Statistical Analysis  
The hypothesis of no effect regarding the discontinuation of PGA on the 
biomechanical properties was examined by a linear mixed-effect model using the 
nlme package in R. Random-effects and was defined on two levels: the patient 
(level-1) and the eye within each patient (level-2). Those random-effects were 
added to the model to account for the intra-individual variance due to the 
repeated-measure design. Age was also included in the model as a covariate.  
Contrasts between the eyes and times were estimated using adjusted p-values to 
control for familywise error rate using multcomp package in R.24  
 
 
35 
 
3.6 Results 
Seventy eyes of 35 patients (16 males and 19 females) with open angle 
glaucoma were recruited. The mean age (± Standard Deviation) was 69.0.5 ± 9.3 
years (range 50 to 85 years). The mean spherical equivalent was +0.25 ± 3.75 D 
(range -6.00 to +4.25 D). At the time of enrollment, patients were on PGA for 4 ± 
2 years (range 1 to 7 years). The topical PGA used included: bimatoprost 
(Lumigan RC, Allergan Inc, Markham, ON, Canada) (8 patients); latanoprost 
(Xalatan, Pfizer Canada Inc, Kirkland, QC, Canada) (15 patients) and (APO 
Latanoprost, Apotex Pty Ltd, Macquarie Park, NSW) (1 patient); and travoprost 
(Travatan Z, Alcon Canada Inc, Mississauga, ON, Canada) (11 patients). 
Corneal Hysteresis 
A statistically significant increase in CH was found between Visit 1 (on PGA) and 
Visit 2 (no PGA) in the study eyes (Figure 11A), with mean (±Standard Error) 
values of 8.98 ± 0.29 mmHg and 10.35 ± 0.29 mmHg, respectively, 
corresponding to a mean increase of 1.37 ± 0.18 mmHg (p < 0.001). A significant 
reduction of 1.25 ± 0.18 mmHg (p < 0.001) was also observed between Visits 2 
and 3, with a final mean CH value of 9.09 ± 0.29 mmHg. In addition, a statistically 
significant difference between the study and control eyes was only observed at 
Visit 2 (1.01 ± 0.23 mmHg; p < 0.001) and not at Visits 1 and 3.  
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Figure 11A: CH Expected Mean in mmHg (± s.e.) across time for each eye 
 
Corneal Resistance Factor 
A statistically significant increase in CRF was found between Visits 1 and 2 in the 
study eyes (Figure 11B), with mean values of 10.23 ± 0.34 mmHg and 11.71 ± 
0.34 mmHg, respectively. CRF was then reduced by 1.90 ± 0.21 mmHg (p < 
0.001) between Visits 2 and 3, with a final mean CRF value of 9.81 ± 0.34 
mmHg. A statistically significant difference between the study and control eyes 
was only observed at Visit 2 (1.46 ± 0.23 mmHg; p < 0.001).   
 
Figure 11B: CRF Expected Mean in mmHg (± s.e.) across time for each eye 
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A statistically significant increase in CCT was found between Visits 1 and 2 in the 
study eyes (Figure 11C), with mean values of 541.83 ± 7.27 µm and 551.91 ± 
7.27 µm respectively, corresponding to a mean increase of 10.09 ± 0.94 µm (p < 
0.001). CCT then decreased by 9.40 ± 0.94 µm (p < 0.001) between Visits 2 and 
3, with a final mean value of 542.51 ± 7.27 µm. A difference between the study 
and control eyes was only recorded at Visit 2 (11.26 ± 1.79 µm; p < 0.001).  
 
Figure 11C: CCT Expected Mean in µm (± s.e.) across time for each eye 
 
Goldmann Intraocular Pressure 
Similarly, a significant increase in IOP was observed between Visits 1 and 2 in 
the study eyes (Figure 11D), with mean values of 15.37 ± 0.54 mmHg and 18.37 
± 0.54 mmHg respectively, corresponding to a mean increase of 3.0 ± 0.49 
mmHg (p < 0.001). A significant reduction of 2.83 ± 0.49 mmHg (p < 0.001) was 
observed between Visits 2 and 3, with a final mean IOP value of 15.54 ± 0.54 
mmHg. The control and study eyes only differed at Visit 2 (1.91 ± 0.49 mmHg; p 
< 0.001), confirming the effectiveness of PGA treatment.  
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Figure 11D: IOP Expected Mean in mmHg (± s.e.) across time for each eye 
IOP Bias  
At Visit 1, the IOP bias (IOPcc – Goldmann IOP) was similar in both groups, all 
eyes at that time being on long term PGA medication, with mean values of 4.1 ± 
0.54 mmHg in the control eyes and 4.8 ± 0.54 mmHg in the study eyes. At Visit 2, 
after a 6 week washout of PGA, the IOP bias in the tested eye was reduced to 
1.6 ± 0.54 mmHg (p<0.001), meaning that underestimation of IOP by Goldmann 
tonometry was significantly less than at Visit 1 (Figure 11E). The difference in 
mean IOP bias between the study and control eyes at Visit 2, however, did not 
reach statistical significance (p= 0.124).  A marginally significant increase of 1.53 
± 0.60 mmHg (p = 0.055) was observed between Visits 2 and 3 in the study eyes, 
with a final mean IOP bias value of 3.10 ± 0.54 mmHg in the study eyes and 2.8 
± 0.54 mmHg in the control eyes. The IOP bias in control eye was changed as 
well during the visits. The IOP bias is estimated as the difference between IOPcc 
– Goldmann IOP. The mean IOP and IOPcc in control eyes at the Visit 1 was 
15.571 mmHg and 19.714 mmHg respectively with IOP bias 4.143 mmHg. As 
shown at Figure 11D the Goldmann IOP increased at Visit 2 up to 16.457 mmHg 
8
10
12
14
16
18
20
22
24
Visit 1 Visit 2* Visit 3
G
o
ld
m
an
n
 IO
P
 (
m
m
H
g)
 
*p-value < 0.001 
Control
Study
 
 
39 
 
that caused decreasing in IOP bias up to 2.792 mmHg. The Goldmann IOP at 
Visit 3 decreased up to 15.886 mmHg but because of decreasing in IOPcc at 
Visit 3 the IOP bias remained unchanged. The curve of the control eye during the 
visits at Figure 11E deviated depend on these changes in GAT IOP and IOPcc. 
The changes in control eye during visits confirmed that these processes not 
understood well and further researches should be conducted with more precise 
IOP control. It can be achieved by using systemic or topical IOP lowering 
medications that control IOP and do not influence biomechanical properties of the 
cornea. 
 
Figure 11E: IOP Bias (Corrected IOP – Goldmann IOP) Expected Mean in 
mmHg (± s.e.) across time for each eye 
 
Visual Field Mean Defect and CH 
We then tried to determine if a low CH was associated with signs of more severe 
glaucoma damages among our open-angle glaucoma patients treated with PGA. 
When considering all eyes on PGA at the time of the first visit, no association 
was found between VF damage and CH. However, when considering only eyes 
with more advanced glaucoma (defined by a VF MD < -6.0 db and represented in 
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red Figure 12), a significant positive correlation was observed between VF MD 
and CH (B = 0.65; p = 0.003).  A lower CH was associated with a more negative 
visual field MD value. 
 
Figure 12: Visual Field Mean Defect on CH by glaucomatous damage 
3.7 Discussion 
This study demonstrated the influence of PGA on the biomechanical properties of 
the cornea and IOP in glaucomatous eyes. It was shown that chronic uses of 
PGA not only reduce IOP but also lowered CH, CRF and CCT. To our 
knowledge, this is the first study that supports the hypothesis that PGA reduces 
CH in glaucomatous eyes. This observation is clinically relevant as a low CH is 
known to be associated with underestimation of IOP5, 51, 52 and with a greater 
susceptibility to glaucoma-related damage. A low CH is recognized as a 
predictive factor for visual field progression.53,54 In the context of our study, this 
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reduction in biomechanical properties of the cornea induced by the administration 
of topical PGA was reversible as a 6-week period of abstinence of PGA use 
resulted in a statistically significant increase in CH, CRF and CCT. 
One of the strengths of our study was the use of a repeated-measures design. 
This design is much more powerful in detecting significant differences across the 
pair of eyes and across times because each subject is his own control. The 
strength of this study also was that no dropouts were recorded, resulting in a well 
balanced design. 
PGAs & CH  
Studies regarding the effects of PGA on CH have already been conducted; 
however, these studies compare the effects of PGA on CH to untreated 
baselines. Two recent studies by Agarwal et al. and by Tsikripis et al. have found 
a sustained increase in CH following the administration of PGA medication. Both 
studies conducted their experiments on open-angle glaucoma patients selected 
using an inclusion criteria similar to those used in our study and with a similar 
age range.55, 56  
One of the main methodological differences involved the duration of PGA therapy 
at the time of the study involvement. While the two studies began from untreated 
baseline55, 56, our participants were previously undergoing daily PGA treatment 
for 4 ± 2 years prior to the start of the study.  
Upon further analysis of the results collected from Tsikripis et al., we discovered 
that the magnitude of increase in CH is not significant if the mean CH differences 
are measured with respect to the CH value obtained after 1 year of treatment.56   
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CH and CRF are related, but are different measurements 
In a study conducted by Shah et al., it was found that CH and CRF are 
significantly correlated and have a correlation coefficient of 0.8. Despite the 
relationship, the study also illustrated that CH and CRF do not reflect the same 
parameter.57 This finding justified our examination of the effects of PGA on CRF. 
Previous studies have examined the effects of PGA on CRF; however, the 
literature contains mixed conclusions.  A study conducted by Detry-Morel et al., in 
which 75 of 108 glaucomatous eyes and 9 of 22 ocular hypertensive eyes were 
treated with PGA prior to the ORA measurements, reported a decrease in CRF 
following PGA use.58 This is in agreement with the findings of our study. 
However, the previously mentioned study conducted by Tsikripis et al. reported 
no change in CRF following PGA treatment.56 The results may be explained by 
the timing of data collection during the period of PGA treatment. In addition, 
based on the correlation between CH and CRF, the manipulations affecting one 
parameter may stimulate a similar response in the other. Figure 13 shows the 
comparative characterization of the researches related to impact of topical PGA 
on the biomechanical properties of the cornea.  
Visual Field Mean Defect and CH 
As previously mentioned, the biomechanical properties of the cornea play crucial 
roles in glaucoma-related damages and progression. While CCT only represents 
one parameter of the corneal properties, the CH is a direct measurement of the 
biomechanics of the whole eye.59 Previous studies found that CCT is associated 
with visual field loss and progression of OHT to glaucoma.54,60  Moreover, 
 
 
43 
 
Congdon NG et al. showed that glaucomatous visual field loss is associated with 
low CH and is independent of CCT.54  
Figure 13: The comparative characterization of the researches related to 
topical PGA. 
 
The association between CH and optic disc surface compliance described by 
Wells A.P. et al. suggests that a floppy cornea is associated with floppy lamina 
Author Aim of Study # of eyes 
/patients 
 
Follow-
up 
 
Pts. 
ages 
groups  
Refra
ction 
Rx 
genera
l 
Diagnosis Rx oc. Investigati
on 
 
Analysis 
 
Conclusion(s) of the study 
Kim 2011 Retrospective PGA vs 
CCT 
166 eyes 24 months 43-70  No No  First diagnosis 
NT OAG 
Latanopr. U/S, GAT t-test Long-term use of latanoprost may decrease the CCT in patients with NTG. 
Sen 2008 Prospective PGA vs CCT 188 eyes 6-12-24 
months 
 
45-68  No  Exclude 
steroid 
First diagnosis 
POAG, NTG, 
OHT 
Latanopr., 
Bimatopr. 
U/S, GAT t-test, 
Wilcoxon 
A significant reduction in CCT was observed at the 6, 12 and 24 months 
with latanoprost and bimatoprost.  
Arcieri 
2008 
Prospective PGA vs CCT 68 eyes 4 weeks 39-76  No  No  First diagnosis 
POAG, NTG, 
OHT 
Latan. 
Bimatop. 
Travopr. 
U/S, GAT t-test Latanoprost, travoprost and bimatoprost had no statistically significant 
effect on the blood-aqueous barrier of phakic patients with POAG or OHT. 
Bimatoprost may be associated with a clinically irrelevant reduction in 
mean CCT. 
Zhong 
2012 
Prospective PGA vs CCT  69 eyes 6 and + 
months 
37-65  No  No  First diagnosis 
POAG, NTG, 
OHT 
Latan. 
Bimatop. 
Travopr. 
U/S, GAT t-test Topical therapy with prostaglandin analogues is associated with  
CCT reduction. Latanoprost, travoprost, and bimatoprost have a similar 
effect on CCT. 
Agarwal  
2012 
Retrospective CH vs IOP 
and CCT vs IOP 
109 eyes 24 months 
 
40-70  No  No  POAG PGA, no 
specify  
ORA, U/S, 
GAT 
 
t-test, 
ANOVA 
Although CH is influenced by IOP, baseline CH is independently associated 
with the magnitude of IOP reduction with PGA therapy. 
 
PGA: 
> CH increased 
> predictive value: lower baseline CH yield greater lowering IOP 
 
Detry-
Morel 
2011  
Small 
attempt 
of 
CH/CRF 
vs PGA  
Prospective  CH/CRF, 
ORA and GAT IOP, CCT 
characteristic in 
different groups of Pts  
154 eyes 9 months 
 
34-86  +3.00D 
to -
3.00D 
No  First diagnosis 
POAG, OHT, 
NTG, NP 
Different 
groups of Pts 
+ PGA 
ORA, GAT, 
U/S 
 
 
 
 
 
 
Wilcoxon, 
Chi-square 
test, rank-
sum test, 
Kruskal-
Wallis 
analysis, 
SPSS 
software 
Glaucoma patients have very probably distinctive biomechanical 
properties of the cornea compared to OHT and controls. Both parameters 
may be influenced by many parameters and can otherwise behave 
independently but they do not replace corneal pachymetry assessment in 
the current state of knowledge. Our data supports the hypothesis that a 
low corneal hysteresis could be considered as a risk factor for 
underestimation of IOP which may have potential implications in the 
management of glaucoma patients and glaucoma 
suspects.  Simultaneously, we could confirm that the ORA provide an IOP 
measurement that is independent from central corneal thickness. 
Although CRF appeared only to be influenced by topical medications, 
further stratified multivariate prospective studies are needed to confirm 
these data, and especially to precise the exact influence of antiglaucoma 
medications on the biomechanical properties of the cornea. 
PGA:CH unaffected 
CRF decreased (like with other topical Rx) 
 
Bafa 
2011 
Prospective PGA vs CCT 
 
129 eyes 0-3-6-9-12-
18-24 
months 
 
60-80  No  No  First diagnosis 
POAG 
Latan. 
Bimatop. 
Travopr. 
B-blockr 
U/S, GAT t-test, 
Wilcoxon, 
STATA 
A slight but significant increase in CCT was recorded in the prostaglandin 
group. This was not the case in B-blockers group. 
[[so still a controversy?]] 
Birt 2012 Prospective PGA vs CCT 
 
75 eyes 2-6-12-24 
weeks 
52-72  No  No  First diagnosis 
POAG, OHT 
Latan. 
Bimatop. 
Travopr. 
 
U/S 
?IOP 
ANCOVA They found a statistically significantly association between a lower mean 
IOP and a thinner cornea when baseline IOP is controlled for. The 
magnitude of the relationship is small but may be clinically significant in 
patients with either very thin or very thick corneas. 
Bolivar  
2011 
Prospective PGA vs CCT 
Rabbit 
12 eyes 1 month 
 
n/a n/a n/a Rabbit Travopr. U/S 
?IOP 
Wilcoxon 
test 
Rabbit corneas treated with topical travoprost show a different strain 
response to acute increases in IOP than control eyes. 
Hatanaka 
2009 
Prospective PGA vs CCT 146 eyes 8 weeks 
 
47-85  No  No  First diagnosis 
POAG 
Latan. 
Bimatop. 
Travopr. 
U/S, GAT t-test, 
ANCOVA 
Topical therapy with prostaglandin analogs and bimatoprost is associated 
with CCT reduction over a period of at least 8 weeks. 
Harasym
owycz 
2007 
Prospective PGA vs CCT 379 pts 
 
6 weeks 
 
18-90  No  No  First diagnosis 
POAG, OHT  
travoprost U/S,GAT S-PLUS 
software, t-
test 
Treatment with travoprost decreased IOP significantly and was associated 
with CCT thinning, which had little or no effect on actual IOP decrease. 
Brandt 
2004 
Prospective PGA vs CCT, 
B-blocker vs CCT 
817 eyes 12-60 
months 
47-70  No  Yes  First diagnosis 
POAG, OHT  
PGA and  
β-blocker 
U/S, GAT X2-test, t-
test 
Impact of CCT on IOP response to ttx: 
Individuals with thicker corneas had smaller measured IOP responses to 
ocular hypotensive medication than those with normal or thin corneas. 
Sawada  
2012 
Prospective PGA vs CCT 42 pts 1-3-4-6 
months 
26-74  No  No  First diagnosis 
POAG, NTG 
Latan. 
Travopr 
U/S, GAT ANOVA, 
Wilcoxon, 
U test, 
Stata 
software 
Travoprost has similar effect as latanoprost in reducing the IOP in 
glaucoma patients with relatively low IOPs. The use of prostaglandin 
analogs can decrease the CCT, and this change should be considered when 
the IOPs obtained by GAT are analyzed.   
Schlote 
2009 
Prospective PGA vs CCT 136 eyes 6-12 
months 
34-88  No  No  First diagnosis 
POAG, NTG, 
OHT 
travoprost *OLCR, GAT 
 
MEDCALC 
9.3.6.0 
software 
Topical therapy with the prostaglandin derivate travoprost is accompanied 
by a significant reduction of CCT within one year (6 months) of treatment. 
 
*Non-contact Ocular Low Coherence Reflectometry, Haag-Streit, 
Switzerland 
Tsikripis 
2013 
Prospective PGA vs CH, 
CRF, CCT 
108 eyes 0-6-12-18-
24-30-36 
months 
45-80 No No POAG 66 – 
latanoprost 
42 – 
latan+timolol 
U/S, GAT, 
ORA 
Kolmogoro
v–Smirnov 
and 
Shapiro–
Wilk 
statistics 
It appears that under local PGA treatment, IOP values decreased and CH 
and CCT significantly increased, whereas CRF did not. 
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cribrosa and peripapillary connective tissue structures. 
Hysteresis refers to the ability of the ocular connective tissues to dampen 
pressure changes rather than having characteristics of floppiness or rigidity.59 
The data collected from our study presented an association between CH and 
visual field damages with a positive correlation between low CH and more 
negative MD. Thus, the concept that CH not only represents corneal 
biomechanical properties but also the biomechanical properties of the entire eye 
was confirmed in this study. 
Mechanism of Action of PGAs  
The mechanism by which PGA affect CH is unclear; however, it is has been 
suggested that PGA enhances collagen and extracellular matrix degradation by 
disturbing the normal levels of matrix metalloproteinases (MMPs) and tissue 
inhibitor metalloproteinases (TIMPs).61 
In a study where participants were on PGA medication for a minimum of 1 year 
prior to the start of the study, the chronic use of PGA resulted in significant 
increases in the immunoreactivity of matrix metalloproteinase-1 (MMP-1)  and 
matrix metalloproteinase-9 (MMP-9) in the epithelium and corneal stroma. MMP-
1 is classified as a collagenase. It functions to degrade collagen types I, II and III 
as well as other molecules both belonging and not to the ECM. MMP-9 is 
classified as a gelatinase and can degrade collagens and gelatins.62 In addition, 
a significant reduction in the immunoreactivity of the tissue inhibitor 
metalloproteinase-1 (TIMP-1) was observed in the same corneal compartments. 
MMPs degrade the collagen and the extra-cellular matrix while TIMPs protect 
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from excessive degradation by inhibiting the MMPs.8, 42, 61  The overexpression of 
MMPs and underexpression of TIMPs caused by the prolonged use of PGAs 
results in an enhanced degradation of the corneal collagen and extracellular 
matrix.61 Corneal hysteresis is dependent on the collagen and extracellular matrix 
composition of the cornea.50 Thus, it is possible that the loss of collagen and 
extracellular matrix results in a reduction in CH. 
A possible alternative can be explained by analyzing (Figure 10). Due to the 
discovery of the same PGA receptors on the cornea as on the trabecular 
meshwork, it is possible that PGA decrease CH and CCT by a similar mechanism 
of action as IOP.41, 42 These processes lead to molecular changes in the cornea 
and can be divided into 2 categories based on a time-action parameter: (i) Short 
time-action processes including compression and degradation of the extracellular 
matrix, increased lysis of extracellular connection between collagen molecules or 
fibrils and increased spacing between the collagen fibrils and muscle bundles. 
Also part of this category is the reorganization of the cytoskeleton by activation of 
a molecular transduction cascade (increase in transcription of matrix 
metalloproteinases),7, 8, 63 corneal stromal receptors such as P2X79, 43-46, 64-66 and 
a platelet-activating factor receptor.41, 42, 47, 48, 67 Processes of this category are 
easily reversible. (ii) Long time-action processes including increased apoptosis of 
stromal cells, decreased mRNA expression in the major components of the 
corneal stroma and decreased reproduction of collagen types I and V in the 
cornea by activation of corneal stromal receptors such as P2X79, 43-46, 64-66 and a 
platelet-activating factor receptor41, 42, 47, 48, 67 that are possibly not reversible.  
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Figure 10: The action and interaction of PGA medication in the eye 
 
Clinical Value of our Results 
The results collected in this study have clinical value as a low CH was shown to 
be associated with more glaucoma damages on visual field. It was also 
associated with a greater susceptibility to glaucoma damage.53, 54 Furthermore, 
low CH in combination with low CCT is known to result in underestimation of 
IOP.5, 51, 52  A reduction in CH renders the cornea less resistant to the applied 
force of the Goldmann applanation tonometer, resulting in the observed 
inaccuracies.68 The reading of an underestimated IOP value may lead to the 
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51,52
 
CH depends on:28,51,52,68
 
 
5. Corneal conditions (keratoconus, 
edema, keratitis: ↓CH)  
6. Refractive surgery (Lasik, PRK) (↓CH)  
7. IOP (↑IOP:↓CH; ↓IOP:↑CH) 
8. Age (↓CH) 
CCT depends on:28,51,52,68  
5. Corneal conditions 
(keratoconus:↓CCT; edema, 
keratitis:↑CCT) 
6. Refractive surgery (Lasik, PRK (↓CCT) 
7. IOP (↑IOP:↑CCT) 
8.  Age (↓CCT)  
Prognosis in glaucoma patients 
 
 
Low CH & low CCT  underestimation of IOP28,51,52,68
 
 
High CH & high CCT  overestimation of IOP28,51,52,68
 
 
 
Decreases  
CH
7-9, 41-46, 48, 63-67
 
Decreases  
CCT
7-9, 41-46, 48, 63-67
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implementation of insufficient treatment which may worsen the prognosis of 
glaucoma.  
The Importance of our Study 
This study provides a new understanding of glaucoma management and 
highlights the importance of corneal hysteresis in the therapy and prognosis of 
glaucoma. This study also suggests using the Goldmann applanation tonometer 
in combination with a device that considers the corneal biomechanical properties, 
such as the ORA, for the measurement of IOP.  
3.8   Conclusions and Perspectives 
Topical prostaglandin analogs reduce corneal hysteresis, central corneal 
thickness and intraocular pressure measurements in glaucoma patients. These 
changes in corneal hysteresis and central corneal thickness affect IOP readings 
and should be taken into account when evaluating IOP lowering response to 
PGA medications. To better understand the action of topical prostaglandins on 
the biomechanical properties of cornea, further research should be conducted. 
To discern an interaction between IOP and corneal hysteresis, further research 
should be conducted with intraocular pressure control. It can be achieved by 
using systemic medications that decrease IOP and do not influence 
biomechanical properties. It can also be achieved by using Pascal dynamic 
contour tonometry or a similar tonometer that does not depend on the 
biomechanical properties of the cornea. 
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